| Literature DB >> 27042848 |
S Fuji1,2, A Rovó3, K Ohashi4, M Griffith5, H Einsele2, M Kapp2, M Mohty6, N S Majhail7, B G Engelhardt8, A Tichelli9, B N Savani8.
Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients frequently develop glucose intolerance and post-transplant diabetes mellitus (PTDM). The clinical importance of PTDM and its detrimental impact on HSCT outcomes are under-recognized. After allo-HSCT, various mechanisms can contribute to the development of PTDM. Here we review information about hyperglycemia and PTDM after allo-HSCT as well as PTDM after solid organ transplantation and describe ways to manage hyperglycemia/PTDM after allogeneic HSCT. Taking into consideration a lack of well-established evidence in the field of allo-HSCT, more studies should be conducted in the future, which will require closer multidisciplinary collaboration between hematologists, endocrinologists and nutritionists.Entities:
Mesh:
Year: 2016 PMID: 27042848 DOI: 10.1038/bmt.2016.81
Source DB: PubMed Journal: Bone Marrow Transplant ISSN: 0268-3369 Impact factor: 5.483